Verrica Pharmaceuticals Inc. (VRCA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Verrica Pharmaceuticals reported revenue of $35.6M, up 370.2% from $7.6M the year before. Net income was -$17.9M (a -50.3% net margin), or -$1.68 per diluted share. Operating margin was -34.2%. Operating activities generated -$17.6M of cash, leaving -$17.6M of free cash flow. At fiscal year end, Verrica Pharmaceuticals held $47.1M in total assets against $22.4M in total liabilities, including $30.1M of cash and equivalents.
Open the full interactive Verrica Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Verrica Pharmaceuticals Key Stats
| Share Price | $3.58 |
|---|---|
| Market Cap | $76.3M |
| Revenue YoY Growth | +370.2% |
| 52-Week Range | $3.28 – $9.10 |
| Shares Outstanding | 21.3 million (basic, 2026 Q2) |
Verrica Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $12.0M | $9.0M | $5.1M | $7.6M | $35.6M |
| Gross Profit | — | — | — | $4.6M | $5.0M | — |
| Operating Income | -$40.2M | -$30.9M | -$21.3M | -$65.8M | -$65.9M | -$12.2M |
| Pre-Tax Income | -$42.7M | -$35.1M | -$24.5M | -$67.0M | -$76.6M | -$17.9M |
| Income Tax | — | — | — | $0 | $0 | $0 |
| Net Income | -$42.7M | -$35.1M | -$24.5M | -$67.0M | -$76.6M | -$17.9M |
| Diluted EPS | -$17.10 | -$13.00 | -$7.20 | -$14.80 | -$14.80 | -$1.68 |
Verrica Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $14.3M | $5.1M | $5.0M | $5.9M |
| Net Income | -$274,000 | -$8.1M | -$9.7M | -$13.2M |
| Diluted EPS | -$0.03 | -$0.76 | -$0.45 | -$0.62 |
Verrica Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.7M | $15.8M | $34.3M | $69.5M | $46.3M | $30.1M |
| Current Assets | $67.7M | $74.3M | $39.1M | $77.5M | $51.2M | $42.5M |
| Total Assets | $74.2M | $80.1M | $44.7M | $81.6M | $54.1M | $47.1M |
| Current Liabilities | $39.5M | $46.1M | $3.5M | $17.0M | $29.0M | $16.4M |
| Total Long-Term Debt | $35.0M | $40.0M | — | $42.9M | $31.0M | — |
| Total Liabilities | $41.2M | $47.5M | $4.7M | $61.8M | $64.0M | $22.4M |
| Shareholders' Equity | $33.0M | $32.6M | $40.0M | $19.8M | -$9.9M | $24.7M |
Verrica Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$30.2M | -$27.6M | -$18.6M | -$38.6M | -$60.9M | -$17.6M |
| Cash From Investing | -$3.6M | -$998,000 | $54.0M | -$362,000 | -$19,000 | $0 |
| Cash From Financing | $35.2M | $33.6M | -$16.9M | $74.2M | $37.7M | $1.4M |
| Free Cash Flow | -$31.7M | -$28.5M | -$19.0M | -$38.9M | -$61.0M | -$17.6M |
Figures from Verrica Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Verrica Pharmaceuticals financials page for every line item.
Verrica Pharmaceuticals Company Profile
| Ticker | VRCA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | West Chester, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001660334 |
Frequently Asked Questions
What was Verrica Pharmaceuticals' revenue in fiscal 2025?
Verrica Pharmaceuticals (VRCA) reported revenue of $35.6M for fiscal 2025.
What is Verrica Pharmaceuticals' annual revenue history?
Verrica Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $12.0M; 2022: $9.0M; 2023: $5.1M; 2024: $7.6M; 2025: $35.6M.
What was Verrica Pharmaceuticals' net income in fiscal 2025?
Verrica Pharmaceuticals reported net income of -$17.9M for fiscal 2025.
What was Verrica Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Verrica Pharmaceuticals' diluted EPS was -$1.68 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Verrica Pharmaceuticals generate in fiscal 2025?
Verrica Pharmaceuticals generated -$17.6M of free cash flow in fiscal 2025.
What was Verrica Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Verrica Pharmaceuticals reported revenue of $5.9M.
How many shares of Verrica Pharmaceuticals are outstanding?
Verrica Pharmaceuticals reported a weighted average of 21.3 million basic shares outstanding in 2026 Q2.
What is Verrica Pharmaceuticals' market cap?
Based on its latest closing price, Verrica Pharmaceuticals (VRCA) has a market capitalization of about $76.3M.
When does Verrica Pharmaceuticals' fiscal year end?
Verrica Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Verrica Pharmaceuticals headquartered?
Verrica Pharmaceuticals lists its business address in West Chester, Pennsylvania in its SEC filings.